[Clinical evaluation of rifamycin SV in ampules of 250 and 500 mg produced by the Tarchomin Pharmaceutical Plants "Polfa"].
Hanzlik
J
J
Wojnicz
A
A
Wolański
I
I
Grzywnowicz
J
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D002764:Cholecystitis / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D011044:Poland; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D012294:Rifamycins / Q000008:administration & dosage*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D012294:Rifamycins; C023808:rifamycin SV
Ocena kliniczna preparatu rifamycin SV w ampułkach à 250 i 500 mg produkcji Tarchomińskich Zakładów Farmaceutycznych "Polfa".